华东医药：10月13日召开董事会会议

Core Viewpoint - Huadong Medicine (SZ 000963) announced the convening of its 11th third board meeting on October 13, 2025, to review the proposal regarding the second unlock conditions of the restricted stock incentive plan for 2022 [1] Company Summary - For the first half of 2025, Huadong Medicine's revenue composition is as follows: Commercial brokerage and agency accounted for 68.23%, pharmaceutical manufacturing for 33.94%, medical aesthetics for 4.57%, and other businesses for 0.77%, with inter-segment eliminations at -7.5% [1] - As of the report date, Huadong Medicine's market capitalization is 69 billion yuan [1]